Skip to content
Biotechnology

Lithuanian Biotech Pioneer ‘Nando’ Embarks on Global Expansion With New Management Team and Innovative Production Line

Nando 2 mins read

"Nando", a leading Lithuanian-owned biotechnology company known for its groundbreaking work in developing microbiological products for agriculture, that helped to save up to 50M on fertilisers, announces a significant bolstering of its management team and an ambitious expansion of its biotechnological production line. This move is set to position "Nando" not just as a leader in Lithuania but as a formidable player on the international stage.

KAUNAS, LITHUANIA / ACCESSWIRE / May 7, 2024 / In a strategic enhancement of its management team, "Nando" welcomes four seasoned professionals, each bringing a wealth of experience from reputable organizations. Gytis Kubilius, with a solid background in management at "SEB" and "Citadele" banks; Mindaugas Navickas, previously International Sales Manager at "Teltonika Networks"; Arūnas Jusas, former General Manager at "Timac AGRO"; and Giedrė Mockienė, who served as HR Manager at UAB "Yara", are now integral parts of "Nando's" leadership, aiming to spearhead ambitious development projects.

To cater to the surging demand for microbiological alternatives to mineral fertilizers and plant protection products, "Nando" has invested about €3 million in a unique biotechnology line. This investment boosts production volume, enhances productivity, and ensures competitive pricing to meet the escalating market demand. With a technology that is currently patent-pending, "Nando" exports to over 20 countries, including Great Britain, Ukraine, Estonia, Kazakhstan, Latvia, Poland, Romania and beyond.

Justinas Taruška, CEO of "Nando", stated, "Our main goal is to feature a highly automated biotechnological production line. This will not only elevate the agro-biotechnology sector's value in Lithuania but also accelerate sustainable and economically viable agricultural technologies across Europe and other continents." The new production line is renowned for its unique microorganism purification technology, a rarity in the entire Baltic region. It promises an efficient production of stable, high-yield microbiological products in powder form, a technology with limited competition.

The inclusion of new management members, with their extensive international experience, underscores "Nando's" commitment to employee development and its focus on penetrating foreign markets, including Europe, North and South America, Asian and Africa countries. This strategic move coincides with the launch of the new production line for microbiological products.

Founded in 2007, "Nando" stands at the forefront of the biotech industry, developing and manufacturing microbiological products and chemical additives for agriculture. With one of Northern Europe's leading R&D centers and partnerships with global research institutions, "Nando" has introduced over 50 innovative products, vital to the agro, livestock. Currently, the company is intensifying its export activities, with operations spanning over 20 countries in Europe, North and South America, Asian and Africa. The "Nando Group" proudly employs more than 50 professionals dedicated to advancing global biotechnology solutions.

Contact Information:

Milda Gauliene
Marketing specialist
milda@nando.lt
+37066475297

SOURCE: Nando

.

View the original press release on newswire.com.

More from this category

  • Biotechnology
  • 17/05/2024
  • 09:43
The BioMed X Institute

New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim

A new research team at XSeed Labs - a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis. RIDGEFIELD, CT / ACCESSWIRE / May 16, 2024 / XSeed Labs - a collaboration between BioMed X and Boehringer Ingelheim, announces the start of its first research team on the Boehringer Ingelheim campus in Ridgefield, Connecticut. This research team's main objective is to develop complex, physiologically relevant disease models that deepen our understanding of dysfunctional wound healing and fibrosis. The end goal is to study fibrosis, drug delivery strategies, and drug safety in parallel,…

  • Biotechnology, Science
  • 07/05/2024
  • 08:00
Brandon Capital

Funding Australia’s Future Economy: CUREator Deploys $7.21 Million to Propel local Life Sciences Potential

Melbourne, 7th May, 2024 CUREator by Brandon BioCatalyst has announced the deployment of $7.21 million in funding to support eight biotech companies across their…

  • Contains:
  • Biotechnology, Medical Health Aged Care
  • 01/05/2024
  • 10:00
Illumina/Garvan Institute

$27 million to map 50 million human cells and uncover genetic fingerprints of disease

Sydney, Australia, Wednesday, 1 May 2024 - Illumina, Inc. (NASDAQ: ILMN) Embargo and media call: 10 am, Garvan Institute, 384 Victoria St, Darlinghurst NSW With researchers, The Hon. David Harris MP, NSW Minister for Medical Research, and Madeleine Jandura who was diagnosed with ulcerative colitis at age 11. Illumina, a global genomics and human health company, has partnered with the Garvan Institute of Medical Research’s TenK10K project to help transform the treatment of complex diseases, starting with autoimmune diseases, with a joint investment of $27 million AUD. The Garvan Institute plans to map 50 million human cells from 10,000 people…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.